AlphaMark Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $496K | Buy |
643
+5
| +0.8% | +$4.14K | 0.21% | 76 |
|
|
2024
Q3 | $565K | Sell |
638
-160
| -20% | -$144K | 0.2% | 72 |
|
|
2024
Q2 | $722K | Sell |
798
-292
| -27% | -$234K | 0.25% | 59 |
|
|
2024
Q1 | $848K | Sell |
1,090
-127
| -10% | -$90.4K | 0.3% | 54 |
|
|
2023
Q4 | $709K | Sell |
1,217
-59
| -5% | -$34.4K | 0.27% | 58 |
|
|
2023
Q3 | $685K | Sell |
1,276
-8
| -0.6% | -$4.12K | 0.29% | 55 |
|
|
2023
Q2 | $602K | Sell |
1,284
-15
| -1% | -$6.29K | 0.28% | 63 |
|
|
2023
Q1 | $446K | Buy |
1,299
+3
| +0.2% | +$1.01K | 0.2% | 71 |
|
|
2022
Q4 | $474K | Sell |
1,296
-200
| -13% | -$70.9K | 0.24% | 66 |
|
|
2022
Q3 | $484K | Sell |
1,496
-169
| -10% | -$53.5K | 0.24% | 67 |
|
|
2022
Q2 | $540K | Sell |
1,665
-35
| -2% | -$10.5K | 0.25% | 69 |
|
|
2022
Q1 | $487K | Sell |
1,700
-200
| -11% | -$51.5K | 0.18% | 83 |
|
|
2021
Q4 | $525K | Sell |
1,900
-110
| -5% | -$27.9K | 0.18% | 85 |
|
|
2021
Q3 | $464K | Sell |
2,010
-215
| -10% | -$53.1K | 0.17% | 84 |
|
|
2021
Q2 | $511K | Sell |
2,225
-101
| -4% | -$20.3K | 0.19% | 80 |
|
|
2021
Q1 | $434K | Sell |
2,326
-149
| -6% | -$29.1K | 0.17% | 83 |
|
|
2020
Q4 | $418K | Sell |
2,475
-575
| -19% | -$85.9K | 0.16% | 80 |
|
|
2020
Q3 | $451K | Hold |
3,050
| – | – | 0.19% | 67 |
|
|
2020
Q2 | $501K | Sell |
3,050
-170
| -5% | -$26.1K | 0.22% | 60 |
|
|
2020
Q1 | $447K | Buy |
3,220
+20
| +0.6% | +$2.75K | 0.25% | 58 |
|
|
2019
Q4 | $421K | Buy |
3,200
+250
| +8% | +$29K | 0.18% | 67 |
|
|
2019
Q3 | $330K | Sell |
2,950
-144
| -5% | -$16K | 0.14% | 75 |
|
|
2019
Q2 | $343K | Hold |
3,094
| – | – | 0.15% | 71 |
|
|
2019
Q1 | $401K | Buy |
3,094
+275
| +10% | +$33.4K | 0.17% | 68 |
|
|
2018
Q4 | $326K | Sell |
2,819
-489
| -15% | -$54.6K | 0.16% | 75 |
|
|
2018
Q3 | $355K | Hold |
3,308
| – | – | 0.14% | 98 |
|
|
2018
Q2 | $282K | Sell |
3,308
-98
| -3% | -$8.05K | 0.11% | 107 |
|
|
2018
Q1 | $264K | Sell |
3,406
-474
| -12% | -$38.2K | 0.11% | 102 |
|
|
2017
Q4 | $328K | Sell |
3,880
-924
| -19% | -$78.6K | 0.13% | 92 |
|
|
2017
Q3 | $411K | Buy |
4,804
+2
| +0% | +$164 | 0.17% | 78 |
|
|
2017
Q2 | $395K | Sell |
4,802
-649
| -12% | -$52.9K | 0.17% | 80 |
|
|
2017
Q1 | $459K | Buy |
5,451
+1
| +0% | +$80 | 0.21% | 75 |
|
|
2016
Q4 | $401K | Buy |
5,450
+1,300
| +31% | +$96.8K | 0.21% | 77 |
|
|
2016
Q3 | $333K | Hold |
4,150
| – | – | 0.17% | 83 |
|
|
2016
Q2 | $327K | Buy |
4,150
+100
| +2% | +$7.53K | 0.19% | 80 |
|
|
2016
Q1 | $292K | Buy |
4,050
+250
| +7% | +$18.9K | 0.16% | 80 |
|
|
2015
Q4 | $320K | Hold |
3,800
| – | – | 0.16% | 78 |
|
|
2015
Q3 | $318K | Sell |
3,800
-300
| -7% | -$25.3K | 0.18% | 77 |
|
|
2015
Q2 | $342K | Hold |
4,100
| – | – | 0.19% | 81 |
|
|
2015
Q1 | $298K | Hold |
4,100
| – | – | 0.17% | 82 |
|
|
2014
Q4 | $283K | Hold |
4,100
| – | – | 0.17% | 82 |
|
|
2014
Q3 | $266K | Buy |
4,100
+250
| +6% | +$15.8K | 0.17% | 86 |
|
|
2014
Q2 | $239K | Hold |
3,850
| – | – | 0.14% | 93 |
|
|
2014
Q1 | $227K | Hold |
3,850
| – | – | 0.14% | 92 |
|
|
2013
Q4 | $196K | Buy |
3,850
+1,250
| +48% | +$62.6K | 0.12% | 94 |
|
|
2013
Q3 | $131K | Hold |
2,600
| – | – | 0.08% | 112 |
|
|
2013
Q2 | $128K | Buy |
+2,600
| New | +$141K | 0.08% | 119 |
|
Other funds holding LLY
AlphaMark Advisors's LLY Position: Q4 2024 in Review
AlphaMark Advisors increased its Eli Lilly (LLY) stake by 0.78% in Q4 2024, buying an estimated $4.14K and bringing the position to 643 shares worth $496K. The position accounts for 0.21% of the portfolio, ranked #76.
AlphaMark Advisors first reported a position in LLY in Q2 2013 and has held it in 47 quarters since. The position peaked at $848K in Q1 2024. 3,907 funds tracked by Wall St. Rank hold LLY as of Q4 2024.
- AlphaMark Advisors held 643 shares of Eli Lilly worth $496K as of Q4 2024.
- AlphaMark Advisors bought 5 Eli Lilly shares in Q4 2024, an estimated $4.14K.
- Eli Lilly made up 0.21% of AlphaMark Advisors's portfolio in Q4 2024, its #76 holding.
- AlphaMark Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 47 quarters since.
- AlphaMark Advisors's Eli Lilly position peaked at $848K in Q1 2024.
- 3,907 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2024.
Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.